Sukumar Nagendran - 23 Jan 2026 Form 4 Insider Report for Taysha Gene Therapies, Inc. (TSHA)

Reporting relationship: President and Head of R&D, Director
Issuer ticker: TSHA
Reported as of: 23 Jan 2026
Net transaction value: -$547,469
SEC form: 4
Accepted by SEC: 27 Jan 2026, 16:05:16 UTC
Prior SEC filing: 14 Jan 2026
Next SEC filing: 13 Apr 2026
Source filing: View source filing
Reporting owner signature: /s/ Kamran Alam, Attorney-in-Fact

Filing notes and source

Key filing fact

Sukumar Nagendran filed Form 4 for Taysha Gene Therapies, Inc. (TSHA) on 27 Jan 2026.

Key facts

This page summarizes Sukumar Nagendran's Form 4 filing for Taysha Gene Therapies, Inc. (TSHA).
2 reported transactions and 0 derivative rows are listed below.
Accepted by SEC: 27 Jan 2026, 16:05.

Change

Previous filing in this sequence was filed on 14 Jan 2026.
Current net transaction value: -$547,469.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001665124 Primary reporting owner

Nagendran Sukumar

Relationship: President and Head of R&D, Director
Address: C/O TAYSHA GENE THERAPIES, INC., 3000 PEGASUS PARK DRIVE, SUITE 1430, DALLAS
Signature: /s/ Kamran Alam, Attorney-in-Fact
Signature date: 27 Jan 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

TSHA transaction

Common Stock

Sale

Transaction value: $423,377
Shares: -89,132
Change %: -6.2%
Price: $4.75
Shares after: 1,344,307
Date: 23 Jan 2026
Ownership: Direct
Footnotes: F1, F2

TSHA transaction

Common Stock

Sale

Transaction value: $124,092
Shares: -26,918
Change %: -2%
Price: $4.61
Shares after: 1,317,389
Date: 26 Jan 2026
Ownership: Direct
Footnotes: F1, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

The Reporting Person is selling the securities set forth herein pursuant to a mandatory sell-to-cover arrangement for the purpose of satisfying income tax liabilities incurred upon vesting of restricted stock unit awards only.

Footnote F2

The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.635 to $4.99 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3).

Footnote F3

The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.505 to $4.715 inclusive.